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httcense.Abstract Background: Patients with chronic obstructive pulmonary disease (COPD) commonly
require hospitalization and admission to intensive care unit. It is useful to identify patients at the
time of admission who are likely to have poor outcome. This study was carried out to deﬁne the
predictors of mortality in mechanically ventilated COPD patients and to advice a scoring system
using the baseline physiological variables for prognosticating these patients.
Methods: This study comprised 220 patients with acute respiratory failure (ARF) secondary to
COPD, requiring mechanical ventilation (MV) and admitted to the intensive care unit (ICU) of
Menouﬁya Chest Department over a two-year period. Clinical and demographic data including
APACHE III (Acute Physiology and Chronic Health Status Evaluation) score and Charlson
co-morbidity score were recorded on MV, at the time of admission to the ICU. In addition, the acid
base status, renal and liver functions, serum electrolytes, LDH, CRP and albumin were recorded at
the time of presentation. The length of stay in-hospital, in the ICU, and mechanical ventilation were
also recorded.
Results: The mean serum albumin level was 2.77 ± 0.39 gm/dL and 2.11 ± 0.19 for survivors
and non-survivors, respectively (p< 0.05). As regards ABGs; the mean PaCO2 was
54.8 ± 6.39 mmHg & 76.1 ± 11.1, PaO2 was 54.8 ± 7.1 mmHg & 50.2 ± 4.9, and HCO3 was
34.7 ± 4.2 mEq/L & 41.6 ± 4.8 in survivors and non-survivors, respectively (p< 0.05). Charlson
co-morbidity index demonstrated a cut off value of 1.4 ± 0.3 & 2.6 ± 0.6 and APACHE III score
off value was 45.2 ± 12.62 & 80.9 ± 15, for survivors and non-survivors, respectively with statis-
tically signiﬁcant correlation for both indices (p< 0.05).est Department, Menouﬁya
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68 R.M. Bakr et al.Conclusion: The present results indicate that the severity scores, like Charlson co-morbidity and
APACHE III scores, are useful and reliable tools for predicting mortality in COPD patients requir-
ing MV. Serum albumin level, renal functions as well as the oxygenation and ventilation parameters
can also, predict mortality.
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COPD is one of the leading causes of death and disability
worldwide. According to statistics, it is expected to move from
its status in 2000 as the 4th and 12th most frequent cause of
mortality and morbidity, respectively, to be the 3rd and 5th
leading cause of mortality and morbidity, respectively, in
2020. Moreover, about 10% of all hospitalizations are directly
or indirectly attributable to COPD [1].
Past deﬁnitions of COPD have been pessimistic at best,
indicating that the disease process is irreversible and that ther-
apy has little to offer. However, a more optimistic view has
come to be widely accepted. The Global Initiative for Chronic
Obstructive Lung Disease (GOLD) guidelines deﬁne COPD as
a disease state characterized by airﬂow limitation that is not
fully reversible, is usually progressive, and is associated with
an abnormal inﬂammatory response of the lungs to inhaled
noxious particles or gases. This GOLD characterization repre-
sents a paradigm shift it suggests that the disease is treatable
and preventable [2].
Risk factors for early mortality are much the same as those
for risk for exacerbations. Among patients who are hospital-
ized, risks for in-hospital mortality include PaO2/FiO2 ratio,
APACHE (Acute Physiology and Chronic Health Status Eval-
uation) scores on admission, low serum albumin (a measure of
nutritional status), the presence of cor-pulmonale, poor exer-
cise capacity, and long-term oral steroid use. Indices of several
respiratory and systemic risk factors seem to have better predic-
tive capacity than the individual factors themselves [3].
Hospitalization carries a substantial risk for mortality and
often indicates a rapid course toward death. Post-discharge
survival is of the same order as that reported for heart failure,
with an estimated 5-yr survival of 35% to 45% [4].
Risk factors for mortality post-discharge are similar to
those during hospitalization. Duration of hospital stay is a pre-
dictor, reﬂecting the severity of illness and increased risk of
nosocomial infection during hospitalization.
Long-term oral steroid use in patients with emphysema
should be avoided; this issue needs to be reemphasized,
especially among the personnel of primary care community [5].
Aim
The purpose of this study is to assess the predictors of mortal-
ity in COPD patients who required invasive MV for ARF.
Methods
This study included 220 patients, with a history of COPD
requiring MV due to ARF, admitted to the intensive care unit
of Menouﬁya Chest Department, over a period of 2 years.The diagnosis of COPD was made by the clinical history,
clinical criteria with compatible physical ﬁndings, and/or evi-
dence of hyperinﬂation on chest radiograph in support of the
diagnosis of COPD. An exacerbation was deﬁned by the pres-
ence of an increase in at least two of the three following symp-
toms: dyspnea, cough and sputum purulence severe enough to
warrant hospital admission.
Patients were excluded from the study if they had an exist-
ing tracheostomy. Patients were eligible for only a single
enrollment in this study.
*All the selected patients were subjected to:-
1. Complete history taking with special stress on; age, gen-
der, smoking index and the use of corticosteroids which
is deﬁned as the daily use of oral corticosteroids for at
least 4 weeks in a dosage of at least 5 mg prednisolone
or equivalent.
2. Thorough clinical examination with special stress on
body mass index (BMI).
3. Routine laboratory investigation as a part of general
assessment including CBC, serum albumin, renal func-
tions, serum electrolytes, CRP, LDH and ABG with
assessment of determinants of perfusion (A-aO2 differ-
ence and PaO2/FiO2).This approach at the time of
admission was taken since the ABG levels can be altered
by the tidal volumes from a mechanical ventilator or by
therapeutic measures to relieve airway obstruction.
4. Chest X-ray.
5. APACHE III score (acute physiology and chronic
health evaluation III scoring system) measured 6 h after
intubation. It’s calculated from 12 routine physiological
measurements, such as blood pressure, body tempera-
ture, heart rate, etc., information about previous health
status, and some information obtained at admission
(such as age). The calculation method is optimized for
paper schemas, by using integer values and reducing
the number of options so that data ﬁt on a single-sheet
paper form. The APACHE III scores range from 0 to
299 [6].
6. Lengths of hospital stay (LOS), duration of; ICU stay
and mechanical ventilation.
7. Determinants of ventilation [tidal volume (Vt), respira-
tory rate (f), minute ventilation (VE).
8. Charlson index; [7] it predicts the ten-year mortality for
a patient who may have a range of co-morbid conditions
such as heart disease, AIDS, or cancer (a total of 22 con-
ditions). Each condition is assigned with a score of 1, 2,
3 or 6 depending on the risk of dying associated with this
condition. Then the scores are summed up and given a
total score which predicts mortality. The clinical condi-
tions and scores are as follows:
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peripheral vascular disease, dementia, cerebrovascular
disease, chronic lung disease, connective tissue disease,
ulcer, chronic liver disease.
2. Each: Hemiplegia, moderate or severe kidney disease,
diabetes, diabetes with complication, tumor, leukemia,
lymphoma.
3. Each: Moderate or severe liver disease.
4. Each: Malignant tumor, metastasis, AIDS.
Statistical analysis
Collected data processed using SPSS (Statistical Program for
Social Science) version16 to be analyzed as follows: quantita-
tive variables as mean (SD) and range, qualitative variables
as number and percentage. Chi-square X2 and Fisher’s exact
test were performed. P-value 6 0.05 was considered statisti-
cally signiﬁcant. ROC (Operating Characteristic curve analy-
sis) curve was used to assess cut-off value speciﬁcity and
sensitivity.
Results
The selected patients of the study were divided into two
groups; survivors and non-survivors.
Comparison between both groups showed no statistical sig-
niﬁcance as regards age, sex, smoking index and BMI [Table 1].
12 patients were receiving steroids for more than 4 weeks at
the time of admission; 8 of them didn’t survive while 4 patientsTable 1 Demographic data and outcome predictors of the studied
Characteristics all patients Survivors
Number of patients 114
Age (years) 60.32 ± 5.
Sex (female/male) 29/191 13/101
Smoking index (pack/year)52.36 ± 12.95 38 ± 33.5
The use of steroid (patients)12 4 (3.5%)
BMI (kg/m2) 30.21 ± 5.2 27.9 ± 3.4
Charlson index 1.8 ± 0.8 1.4 ± 0.3
Albumin (gm/dL) 2.88 ± 0.25 2.77 ± 0.3
Urea (mg/dL) 85.63 ± 4.58 81.69 ± 31
Creatinine (mg/dL)1.66 ± 0.22 1.54 ± 0.4
CRP (mg/L) 158.3 ± 10.25 141.5 ± 9.
LDH (mg/L) 299.2 ± 17.73 271.5 ± 15
Na (mEq/L) 125.41 ± 15.2 132.1 ± 2.
K (mEq/L) 2.99 ± 1.24 3.32 ± 0.1
pH 7.10 ± 0.55 7.24 ± 0.0
PaCO2 (mmHg) 66.32 ± 3.52 54.8 ± 6.3
PaO2 (mmHg) 51.26 ± 1.47 54.8 ± 7.1
HCO3 (mEq/L) 37.51 ± 4.88 34.7 ± 4.2
LOS in hospital (days)11.52 ± 4.22 5.8 ± 0.97
LOS in ICU (days) 5.8 ± 0.97
LO MV (days) 0 5.07 ± 1.5
f/Vt 100 ± 10
PA-aO2 (mm Hg) 17.9 ± 2.3
PaO2/FiO2 280 ± 45
APACHE III2 45.2 ± 12.
*Data are presented as mean ± SD or No. NS: Non-signiﬁcant; BMI: Bod
LO: Length of; MV: Mechanical ventilation; f/Vt: Frequency/Tidal volum
oxygen tension/Fraction of inspired oxygen; APACHE III: Acute physiosurvived with higher mortality in those using steroids more
than 4 weeks of statistical signiﬁcance [Table 1].
Also, there was no statistical signiﬁcance as regards serum
sodium and potassium levels, LDH and CRP (p> 0.05) [Ta-
ble 1].
The mean serum albumin level was 2.77 ± 0.39 gm/dL and
2.11 ± 0.19 for survivors and non-survivors respectively,
which was statistically signiﬁcant (p< 0.05) [Table 1].
The renal function tests were compared in both groups and
it showed increasing mortality with the rising in all renal func-
tion parameters.
The mean blood urea level was 81.69 ± 31.1 mg/dL &
102.8 ± 36.1 and serum creatinine 1.54 ± 0.47 mg/dL &
1.77 ± 0.70, for survivors and non-survivors respectively,
which was statistically signiﬁcant (p< 0.05) [Table 1].
The ABGs were compared in both groups and it showed in-
crease in mortality with derangement of all items of ABGs,
with mean pH 7.24 ± 0.03 & 7.20 ± 0.01, PaCO2
54.8 ± 6.39 mmHg & 76.1 ± 11.1 , PaO2 54.8 ± 7.1 mmHg
& 50.2 ± 4.9 and HCO3 34.7 ± 4.2 mEq/L & 41.6 ± 4.8 for
survivors and non-survivors respectively, which was signiﬁcant
(p< 0.05) [Table 1].
The f/Vt at time of weaning was compared in both groups
and showed marked increase in mortality with the rising of this
index. The mean f/Vt was 100 ± 10 & 65 ± 40 for survivors
and non-survivors respectively, with statistically signiﬁcant
correlation (p< 0.05) [Table 1].
The PA-aO2 at the time of admission was compared in both
groups and showed marked increase in mortality with in-
creased oxygen difference. The mean PA-aO2 waspatients.
Non-survivors p-value
106
25 69.98 ± 6.97 NS
16/90 NS
62.82 ± 29.68 NS
8 (7.5%) 0.041
7 36.7 ± 3.22 NS
2.6 ± 0.6 0.009
9 2.11 ± 0.19 0.049
.1 102.8 ± 36.1 0.001
7 1.77 ± 0.70 0.047
6 179.6 ± 11.2 NS
.36 282.8 ± 161.1 NS
6 123.1 ± 2.7 NS
5 3.98 ± 1.52 NS
3 7.20 ± 0.01 NS
9 76.1 ± 11.1 0.022
50.2 ± 4.9 0.047
41.6 ± 4.8 0.030
15.1 ± 1.7 0.002
11.4 ± 3.1 0.001
8.83 ± 0.98 0.014
65 ± 40 0.001
6 31 ± 5.99 0.004
180 ± 60 0.002
62 80.9 ± 15 0.001
y mass index; CRP:C-reactive protein; LDH: Lactate dehydrogenase;
e (L); PA-aO2:Alveolar arterial oxygen difference; PaO2/FiO2:Arterial
logy and chronic health evaluation III scoring system.
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Figure 1 ROC curve plotted for Charlson co-morbidity index to
predict outcome of COPD patients in the 1st 6 hr of MV.
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Figure 2 ROC curve plotted for APACHE III to predict
outcome of COPD patients in the 1st 6 hr of MV.
70 R.M. Bakr et al.17.9 ± 2.36 mmHg & 31 ± 5.99 for survivors and non-survi-
vors respectively, with statistically signiﬁcant correlation
(p< 0.05) [Table 1].
The PaO2/FiO2 was compared at time of admission in both
groups and showed marked increase in mortality with the ris-
ing of the index. The mean PaO2/FiO2 was 280 ± 45 and
180 ± 60 for survivors and non-survivors respectively, with
statistically signiﬁcant correlation (p< 0.05) [Table 1].
The Charlson co-morbidity index was compared in both
groups and correlated with the mortality. Its rise showed
marked increase in mortality, with a mean of 1.4 ± 0.3 &
2.6 ± 0.6 for survivors and non-survivors respectively which
was statistically signiﬁcant (p< 0.05) [Table 1].
ROC curve showed that Charlson co-morbidity index cut-
off value was 2.1, with a sensitivity of 69.7% and speciﬁcity
of 81.2% [Fig. 1].The APACHE III was measured for both groups and
showed marked increase in mortality with the rising of the
score. The mean APACHE III was 45.2 ± 12.62 &
80.9 ± 15 for survivors and non-survivors respectively with
statistically signiﬁcant correlation (p< 0.05) [Table 1].
ROC curve showed that APACHE III score cut-off value
was 48 with a sensitivity of 89.6% and speciﬁcity of 75.9%
[Fig. 2].Discussion
The randomly selected patients of the study were divided into
two groups; survivors and non-survivors. It was found that
104 patient died while 116 survived with a mortality rate of
47.27%.
Treating COPD patients with steroids has been linked with
many side effects and increased mortality. In this study 12 pa-
tients were using steroids more than 4 weeks at the time of
admission, 4 patients survived, where 8 of them died [Table
1]. These results coincided with those results reported by Groe-
newegen [4] and Cano et al. [9], who noticed increased mortal-
ity among COPD patients with exacerbations, using oral
steroids, in contrary to the results reported by Nevins et al.
[8], who found insigniﬁcant difference in mortality rates be-
tween steroid users and non users.
The increased mortality among COPD patients receiving
steroids for long periods may be related to its unwanted effects
on respiratory and peripheral muscle strength and its negative
inﬂuence on functional status in these patients [10–15].
The results showed an increase in mortality among COPD
patients with higher BMI, but this was statistically insigniﬁcant
(p> 0.05) [Table 1]. The same result was reported by Gunen et
al. [16], in contrary to the results reported by other researches
like; Ray et al. [10], Cano et al. [9] and Kessler et al. [17], who
found no inﬂuence for the increase in BMI on mortality rates
among COPD patients.
In multiple epidemiologic studies, obesity has been shown
to increase morbidity and mortality, this may be because the
several associated pathophysiologic changes in obese patients
place them at a risk for adverse outcomes in the ICU
[18,5,19–23].
However, in studies of acutely or critically ill patients, the
effect of BMI on outcomes has been mixed. In a retrospective
review, a low BMI (615 percentile), but not high BMI (P85
percentile), was a signiﬁcant and independent predictor of
mortality [21]. The high missing data rate (30%) limits the
interpretability of the ﬁndings. A second study using case-con-
trol design, showed an increased incidence of prolonged
mechanical ventilation, ICU LOS, and hospital mortality for
morbidly obese patients (BMI > 40) [19]. However, other
independent, retrospective studies using a large multi-
institutional ICU database found that low BMI was associated
with increased mortality and worsened hospital discharge
functional status. In fact, their analyses suggest that over-
weight and obese patients may have lower mortality. Again,
the exclusion rate was high because of missing data (35.6%)
[20,23–26].
This study showed that the rise of Charlson co-morbidity
index was correlated with rise in mortality rates (1.4 ± 0.3 &
2.6 ± 0.6 for survivors and non-survivors respectively, which
was statistically signiﬁcant) (p< 0.05) [Table 1]. ROC curve
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with a sensitivity of 69.7% and speciﬁcity of 81.2% [Fig. 1].
These results were close to those described by Nevins et al.
[8], although Gunen et al. [16], showed non-signiﬁcant differ-
ence in Charlson co-morbidity index, with a mean of
1.59 ± 0.8 & 1.61 ± 0.9 for survivors and non-survivors
respectively. However, Aggarwal et al. [27], showed different
ﬁgures, with a mean of 3.8 ± 2.1, which might be because
the studied patients were cirrhotic patients admitted to medical
ICU.
Also, this study showed that the mean serum albumin level
was 2.77 ± 0.39 gm/dL & 2.11 ± 0.19 for survivors and non-
survivors respectively, the difference was statistically signiﬁ-
cant (p< 0.05) [Table 1]. This result was close to those de-
scribed by Nevins et al. [8], and Yıldız et al. [18], which is
not coinciding with the results found by Gunen et al. [16]
and Nava et al. [28], who showed a non-signiﬁcant difference
between the mean serum albumin level for survivors and
non-survivors (3.5 ± 0.5 gm/dL & 3.4 ± 0.8. Aggarwal et al.
[27], reported different results with a lower mean serum albu-
min level of 2.6 ± 0.7 gm/dL, which might be because his
study patients were cirrhotic ones admitted to a medical ICU.
The results of this study showed an increase in mortality
rates with deterioration in the renal function parameters.
The mean blood urea level was 81.69 ± 31.1 mg/dL &
102.8 ± 36.1 and mean serum creatinine level was
1.54 ± 0.47 mg/dL & 1.77 ± 0.70 for survivors and non-survi-
vors respectively, which is statistically signiﬁcant (p< 0.05)
[Table 1]. However, Nava et al. [28], reported an insigniﬁcant
difference between mean serum creatinine level for both
groups (1.1 ± 0.6 mg/dL & 1.0 ± 0.3), respectively [28].
As well, this study showed an increase in mortality with
derangement of all ABGs items, with mean pH 7.24 ± 0.03
& 7.24 ± 0.03, PaCO2 54.8 ± 6.39 mmHg & 76.1 ± 11.1,
PaO2 54.8 ± 7.1 mmHg & 50.2 ± 4.9 and HCO3
34.7 ± 4.2 mEq/L & 41.6 ± 4.8, for survivors and non-survi-
vors respectively, which was statistically signiﬁcant
(p< 0.05) [Table 1]. This was in agreement with Nevins et
al. [8], who demonstrated signiﬁcant differences, but with dif-
ferent ﬁgures; mean pH of 7.26 ± 0.12, mean PaCO2 of
69 ± 28 mmHg and mean PaO2 of 88 ± 62 mmHg. This
might be because ABG testing was performed immediately be-
fore intubation and in a large majority of who were breathing
supplemental oxygen. Gunen et al. [16], described different re-
sults with mean pH 7.41 ± 0.07 & 7.40 ± 0.09, PaCO2
48.2 ± 12.8 mmHg & 55.6 ± 5.6 and PaO2 48.3 ± 13.1 mm
Hg & 40.7 ± 7.7, for survivors and non-survivors, respectively
which was non-signiﬁcant statistically. Kessler et al. [17], dem-
onstrated PaO2 66 ± 10 mmHg and PaCO2 46 ± 8 mmHg as
the lowest required level for survival of COPD patients on
MV. Nava et al. [28], and Yıldız et al. [18], showed signiﬁcant
difference regarding PaO2, PaCO2 but not to pH, for both
groups, with results close to that described by Gunen et al.
[16].
A high PaCO2 was found to be a risk factor for mortality in
several studies. The level of hypercapnia, suggestive of chronic
alveolar hypoventilation, reﬂects the severity of the underlying
respiratory condition and patients with chronic hypercapnia
who constituted the majority of our study population, have a
worse prognosis than patients with normo-ventilation [29–32].
The length of stay (LOS) in-hospital, ICU and on MV were
compared in both groups and it showed marked increase inmortality with the prolonged duration. The mean LOS in hos-
pital was 5.8 ± 0.97 d & 15.1 ± 1.7, in the ICU 5.8 ± 0.97 d
& 11.4 ± 3.1, and on MV 5.07 ± 1.5 d & 8.83 ± 0.98, for sur-
vivors and non-survivors respectively, with a statistically sig-
niﬁcant correlation (p< 0.05) [Table 1]. Nevins et al. [8],
showed different results, although in the same direction, with
a mean LOS in hospital 22.0 ± 20 d, in ICU 12 ± 15 d and
on MV 8.9 ± 4.1 d and Gunen et al. [16], in their study
showed LOS in hospital as 11.4 ± 4.3 d & 14.2 ± 12.1, for
survivors and non-survivors, respectively.
The f/Vt at time of admission was compared in both groups
and showed marked increase in mortality with the rising of this
index. The mean f/Vt was 100 ± 10 for survivors and 65 ± 40
for non-survivors, with a statistically signiﬁcant correlation
(p< 0.05) [Table 1].
Nava et al. [28], found different results of non signiﬁcant
importance with a mean f/Vt of 55.2 ± 16.6 & 69.9 ± 20.8
for survivors and non-survivors respectively, but it was signif-
icant when combined with arterial blood gases parameters.
However, other hand other researchers reported its signiﬁ-
cance alone [28,33].
Also, this study showed a signiﬁcant difference between the
mean value of PA-aO2 for survivors (17.9 ± 2.36 mmHg) and
non-survivors (31 ± 5.99 mmHg), with a statistically signiﬁ-
cant correlation (p< 0.05) [Table 1, Fig-28].
The same thing was recorded for the measured mean value
for PaO2/FiO2, which was 280 ± 45 & 180 ± 60, for both sur-
vivors and non-survivors respectively, with a statistically sig-
niﬁcant correlation (p< 0.05) [Table 1].
In agreement with these results, Park et al. [34], found sig-
niﬁcant differences regarding both PA-aO2 and PaO2/FiO2,
although with different ﬁgures. Their mean PA-aO2 was
36.1 ± 29.9 mmHg & 47.9 ± 36.1 and PaO2/FiO2 was
317.7 ± 86 & 391.9 ± 73.8, for survivors and non-survivors,
respectively. These ﬁgures were recorded in mechanically ven-
tilated COPD patients with septic shock, which might contrib-
ute to the difference between their and our study values. Nava
et al. [28], reported similar results but of insigniﬁcant impor-
tance, that may be because these parameters were estimated
while the patients were still mechanically ventilated.
The results of the current study showed that the mean
APACHE III score was 45.2 ± 12.62 & 80.9 ± 15.82 for sur-
vivors and non-survivors respectively, with a statistically sig-
niﬁcant correlation (p< 0.05) [Table 1]. Similarly, Eapen et
al. [35], found that APACHE III scoring system discriminates
well between survivors and non-survivors in patients admitted
to the ICU after major vascular surgery, but calibration of the
model was poor. Aggarwal et al. [27], showed similar results
but with different ﬁgures (90.1 ± 40.1) for their non-survivor
cirrhotic patients, admitted to medical ICU.
In our study, a cut-off value of 48 for APACHE III score,
has been estimated, with speciﬁcity of 75.9% & sensitivity
89.6%, for predicting mortality in these COPD patients. Other
researchers reported similar sensitivities and speciﬁcities in
several medical ICU based studies approaching the practical
limit of the generalization performance of this type of multi-
variate model [36,37].
However, scoring systems, primarily developed for estimat-
ing prognosis in critically ill patients, have not been well vali-
dated in mechanically ventilated COPD patients. A study was
done to determine the usefulness of these scoring systems on
mechanically ventilated patients and found that APACHE
72 R.M. Bakr et al.III score is an important independent predictive tool to deter-
mine outcome of patients on MV [38]. These data will be a
valuable aid to clinicians and relatives of patients on mechan-
ical ventilation in deciding the probable outcome and manage-
ment decisions. In another study on 500 consecutive patients
admitted to a medical ICU, the newly modiﬁed Organ System
Failure (OSF) score was found to be superior to the APACHE
II score in predicting mortality [39].
APACHE III and APACHE II scores both could be used to
predict outcome and need for intubation and MV, but studies
show that APACHE III is a superior signiﬁcant index as a pre-
dictive tool for ICU stay and duration of MV [40].Conclusion
From this study, we can conclude that among variables avail-
able within the ﬁrst 6 h of MV, the severity scores, as Charlson
and APACHE III scores are useful and reliable tools for
predicting mortality among mechanically ventilated COPD
patients. Serum albumin level, renal functions as well as oxy-
genation and ventilation indices (PaO2, PA-aO2, PaO2/FiO2,
PaCO2), can also predict mortality. Comorbidities such as
non-pulmonary organ dysfunction and metabolic disorders
other than respiratory failure, may make an additional contri-
bution to increased mortality risk in COPD patients who are
admitted to the RICU.
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